GSK's RSV Vaccine, AREXVY, Approved in US for Expanded Age Indication in Adults Aged 18-49 Years at Increased Risk
Forbion Announces Second Exit from Forbion Growth Fund III Following $2.2 Billion Acquisition of RAPT Therapeutics by GSK
PIVOT-PO Phase 3 Data Show Tebipenem HBr's Potential as the First Oral Carbapenem Antibiotic for Patients with Complicated Urinary Tract Infections
New Local Data in GSK and IQVIA's Vaccine Track Supports Smarter Public Health Action at the Community Level
Multiple Myeloma Research Foundation Unites Patients and Advocates to Hike New Hampshire's White Mountains to Accelerate a Cure for Multiple Myeloma
Sankamap Secures Two-Year Prospecting Licence Renewals for District-Scale Kuma and Fauro Copper Gold Properties
BriaCell Engages Consulting and Branding Firms to Support Commercial and Market Access Evaluation of Bria-IMT
